Literature DB >> 18188725

Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.

Hasan Senol Coşkun1, Sema Sezgin Göksu, Mehmet Sahin, Güçhan Alanoğlu.   

Abstract

Imatinib is now indicated as the first line therapy for chronic myeloid leukemia (CML). Treatment of CML with imatinib is generally well tolerated and the risk of severe adverse affects is low. Many new drugs including targeted therapy are combined with antineoplastic agents safely. We here report a patient with CML who developed concurrent mesenchymal tumor while undergoing therapy with imatinib and treated with combination chemotherapy including bleomycin, etoposide, and cisplatin, as well as imatinib without severe toxicity.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18188725     DOI： 10.1007/s12032-007-0053-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  12 in total

1.  Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors:  Barbara Wassmann; Heike Pfeifer; Nicola Goekbuget; Dietrich W Beelen; Joachim Beck; Matthias Stelljes; Martin Bornhäuser; Albrecht Reichle; Jolanta Perz; Rainer Haas; Arnold Ganser; Mathias Schmid; Lothar Kanz; Georg Lenz; Martin Kaufmann; Anja Binckebanck; Patrick Brück; Regina Reutzel; Harald Gschaidmeier; Stefan Schwartz; Dieter Hoelzer; Oliver G Ottmann
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

2.  High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

Authors:  D Rea; L Legros; E Raffoux; X Thomas; P Turlure; S Maury; B Dupriez; A Pigneux; B Choufi; O Reman; D Stéphane; B Royer; M Vigier; M Ojeda-Uribe; C Recher; H Dombret; F Huguet; P Rousselot
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

3.  Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.

Authors:  Faye M Johnson; Lee M Krug; Hai T Tran; Stephanie Shoaf; Victor G Prieto; Pheroze Tamboli; Beverly Peeples; Jyoti Patel; Bonnie S Glisson
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

4.  Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

Authors:  Adrienne de Labarthe; Philippe Rousselot; Françoise Huguet-Rigal; Eric Delabesse; Francis Witz; Sébastien Maury; Delphine Réa; Jean-Michel Cayuela; Marie-Christine Vekemans; Oumedaly Reman; Agnès Buzyn; Arnaud Pigneux; Martine Escoffre; Yves Chalandon; Elizabeth MacIntyre; Véronique Lhéritier; Jean-Paul Vernant; Xavier Thomas; Norbert Ifrah; Hervé Dombret
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

5.  Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.

Authors:  Suzanne George; Jayesh Desai; J Paul Eder; Judith Manola; David P Ryan; Leonard J Appleman; George D Demetri
Journal:  Eur J Cancer       Date:  2006-02-28       Impact factor: 9.162

6.  Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.

Authors:  Roberto Latagliata; Latagliata Roberto; Massimo Breccia; Breccia Massimo; Ida Carmosino; Carmosino Ida; Chiara Sarlo; Sarlo Chiara; Enrico Montefusco; Montefusco Enrico; Marco Mancini; Mancini Marco; Fiammetta Natalino; Natalino Fiammetta; Antonio Chistolini; Chistolini Antonio; Rosa De Cuia; De Cuia Rosa; Eleonora Russo; Russo Eleonora; Giacomo Salvatore Morano; Morano Salvatore Giacomo; Francesca Biondo; Biondo Francesca; Antonio Spadea; Spadea Antonio; Franco Mandelli; Mandelli Franco; Giuliana Alimena; Alimena Giuliana
Journal:  Leuk Res       Date:  2005-03       Impact factor: 3.156

7.  Acute renal failure secondary to imatinib mesylate treatment in prostate cancer.

Authors:  John R Foringer; Regina R Verani; Vincent M Tjia; Kevin W Finkel; Joshua A Samuels; Jayarama S Guntupalli
Journal:  Ann Pharmacother       Date:  2005-11-15       Impact factor: 3.154

8.  In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.

Authors:  Y Kano; M Akutsu; S Tsunoda; H Mano; Y Sato; Y Honma; Y Furukawa
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

9.  [Hematological side effects of tyrosine kinase inhibition using imatinib].

Authors:  A Schmitt-Graeff; A Hochhaus
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

Review 10.  Indications for imatinib mesylate therapy and clinical management.

Authors:  François Guilhot
Journal:  Oncologist       Date:  2004
View more
  1 in total

1.  A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.

Authors:  Michael J Pishvaian; Rebecca Slack; Eunice Y Koh; Jan H Beumer; Marion L Hartley; Ion Cotarla; John Deeken; Aiwu Ruth He; Jimmy Hwang; Shakun Malik; Kashif Firozvi; Minetta Liu; Beth Elston; Sandy Strychor; Merrill J Egorin; John L Marshall
Journal:  Cancer Chemother Pharmacol       Date:  2012-09-27       Impact factor: 3.333
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.